Cryo-Save to launch Cryo-Lip™ in the US

December 16, 2010 Group News

Cryo-Save Group N.V. (Euronext: CRYO, “Cryo-Save”), Europe’s leading stem cell bank, today announced that it intends to launch Cryo-Lip™ in the United States in 2011, after the successful introduction of the service in Europe during 2010. Cryo-Save is one of the first in the world that offers cryostorage of adult mesenchymal stem cells from fatty tissue for use by patients undergoing a surgical procedure. Cryo-Save is currently looking for partners to roll out this service in the United States.

read more

Director/PDMR shareholding

December 15, 2010 Group News

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), Europe’s leading adult stem cell storage bank, has been informed that Mr Walter van Pottelberge, Non-Executive Director, purchased 5,000 ordinary shares of Euro 0.10 (‘Ordinary Shares’) at a price of €4.90 on 13 December 2010.

Following this purchase, Walter van Pottelberge is beneficially interested in 31,210 ordinary shares, representing approximately 0.33% of the Group’s issued share capital.

read more

Cerebral palsy boy treated with own cord blood stem cells

December 14, 2010 Group News

Cryo-Save Group N.V. (Euronext: CRYO, “Cryo-Save”), Europe’s leading stem cell bank, today announces that another sample has been released. A six year old boy from Portugal went to Duke University (USA) to participate in a FDA approved clinical trial for cerebral palsy (CP). Cerebral palsy is a form of brain injury which causes physical disability and has no standard cure at the moment.

read more

Leukemia child now completely cured thanks to her own cord blood stem cells

November 26, 2010 Press Clippings

A world’s first allowed to save a young girl’s life

In 2005, the parents of a four year old girl suffering from leukemia were told their daughter’s chemotherapy had failed. The doctors had lost hope; they gave her a three months prognosis. Five years later, the girl is alive and doing well, she is even considered cured. She was infused by her own cord blood stem cells, which her parents had stored privately. This is the first time an autologous cord blood transplant has cured leukemia.

Source: Life Site News

Director/PDRM shareholding

November 23, 2010 Group News

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), Europe’s leading adult stem cell storage bank, has been informed that Mr Marc Waeterschoot, Executive Director, purchased 20,000 ordinary shares of Euro 0.10 (‘Ordinary Shares’) at a price of €5.10 on 18 November 2010. Following this purchase, Marc Waeterschoot is beneficially interested in 1,853,850 ordinary shares, representing approximately 19.84% of the Group’s issued share capital.

read more

10 years of stem cell storage

November 18, 2010 Group News

Cryo-Save celebrates 10 years of stem cell storage with increasing usage of umbilical cord stem cells

Cryo-Save Group N.V. (“Cryo-Save”) is Europe’s leading stem cell bank, and today announces the 10 year anniversary of storing the first samples of stem cells taken from umbilical cord blood in its laboratories.

read more

EN – Press release TBCCB acquisition

November 3, 2010 Group News

Acquisition of distributor

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), Europe’s leading adult stem cell storage bank, has acquired its Bulgarian distributor, Tissue Bank Cryo Center Bulgaria AD (‘TBCCB’) for an initial consideration of €1.5 million payable in cash and 100,000 Cryo-Save Group N.V. shares, and a deferred performance payment, payable annually on the achievement of certain goals until 2013. The total acquisition price reflects approximately five times EBIT of TBCCB. The Group expects the acquisition to be earnings enhancing with immediate effect.

read more

NL – Press release TBCCB acquisition

November 3, 2010 Group News

Overname van distributeur

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, of ‘de Groep’), de grootste stamcelbank van Europa, heeft zijn Bulgaarse distributeur, Tissue Bank Cryo Center Bulgaria AD (‘TBCCB’), geacquireerd. De overnameprijs bedraagt €1,5 miljoen in contanten en 100.000 aandelen Cryo-Save Group N.V. Daarnaast is gedurende drie jaar een resultaatafhankelijke betaling verschuldigd. De totale acquisitieprijs weerspiegelt ongeveer vijf maal de EBIT van TBCCB. Cryo-Save verwacht dat de acquisitie met onmiddellijke ingang bijdraagt aan de winst per aandeel.

read more

Page 30 of 46« First...1020...2829303132...40...Last »